ZeleFelis

2026/08/21 Product-Level Analysis of mRNA Platforms: Commercial Synergies, Competitive Disruption, and Portfolio Impacts across Merck, Roche, AstraZeneca, and Hengrui Pharma

Disclaimer: This synthesis is provided strictly for academic, research, and informational purposes and does not constitute financial, investment, or medical advice. Product-Level Analysis of mRNA Platforms: Commercial Synergies, Competitive Disruption, and Portfolio Impacts across Merck, Roche, AstraZeneca, and Hengrui Pharma While messenger RNA (mRNA) personalized cancer vaccines have not

2026/08/20 The "Pick-and-Shovel" Play in mRNA Oncology: Maravai LifeSciences (NASDAQ: MRVI)

English Version The Ultimate "Pick-and-Shovel" Play in mRNA Oncology: A Comprehensive Analysis of Maravai LifeSciences (NASDAQ: MRVI) Executive Summary As personalized mRNA cancer vaccines transition from clinical validation to commercial execution, investors are actively seeking high-conviction, asymmetric opportunities. While primary vaccine developers face binary regulatory

2026/08/19 The “iPhone Moment” in Bio-Medicine: A Deep Dive into Personalized mRNA Cancer Vaccines

English Version The “iPhone Moment” in Bio-Medicine: A Deep Dive into Personalized mRNA Cancer Vaccines, Industry Penetration Curves, and Long-Term Valuation Potential The landscape of oncology has reached a monumental inflection point. Moderna, Inc. and Merck & Co., Inc. announced landmark positive topline results from the Phase 3

2026/08/19 Comparative Biopharmaceutical Analysis: Argenx SE(NASDAQ:ARGX) vs. BeiGene Ltd.(HK:06160)

English Version Comparative Biopharmaceutical Analysis: Argenx SE vs. BeiGene Ltd. Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Section I: Argenx SE — The Immunology Powerhouse & "Pipeline-in-a-Product" Paradigm 1. Corporate Strategy: The "Pipeline-in-a-Product&

2026/08/18 Global Biopharma Supply Chain and Synthetic Biology Infrastructure: A Deep Dive into GenScript Biotech（1548.hk） and Twist Bioscience（TWST）

Disclaimer: This research summary is for academic and informational purposes only and does not constitute investment advice or any financial recommendation. Global Biopharma Supply Chain and Synthetic Biology Infrastructure: A Deep Dive into GenScript Biotech and Twist Bioscience 1. Structural Stock Performance and Key Catalysts The global life science tools

2026/08/17 Summit Therapeutics (NASDAQ: SMMT) Deep Dive Equity Research

English Version Summit Therapeutics (NASDAQ: SMMT) Deep Dive Equity Research 1. Company Positioning and Pipeline ArchitectureSummit Therapeutics functions as a single-asset, virtual biotechnology entity whose market capitalization is predominantly underpinned by a single core therapeutic compound: Ivonescimab (AK112/SMMT-112), a first-in-class PD-1/VEGF bispecific antibody.

2026/08/15 Learning Reflections and Knowledge Transfer: My Research Journey from Prairie Operating Co. (PROP) to Healthcare Stocks

Part 1: English From Capital Structure Games in Energy Stocks to Financial Engineering Logic in Biotech Investments Learning Reflections and Knowledge Transfer: My Research Journey from Prairie Operating Co. (PROP) to Healthcare Stocks 1. The Essence of the TransferIn my previous research on Prairie Operating Co. (PROP)—specifically "2026/

2026/08/15 The Mechanics of a Regulatory Debacle: Learning from Capricor Therapeutics (NASDAQ: CAPR)

Disclaimer Disclaimer: This article is strictly for educational, research, and analytical purposes and does not constitute financial, investment, or legal advice. English Version The Mechanics of a Regulatory Debacle: Learning from Capricor Therapeutics (NASDAQ: CAPR) 1. Executive Summary and Background Between mid-2025 and August 2026, Capricor Therapeutics experienced a

2026/08/15 Commercial Models and Investment Dynamics: Rare Disease Specialty Pharma versus Mass Market Pharmaceuticals

Biopharmaceutical commercialization spans two fundamentally distinct business models: rare disease specialty pharmaceuticals and mass-market therapeutics. While broad-population drugs target large patient pools with lower individual therapy value, rare disease therapeutics operate within highly concentrated patient populations characterized by exceptionally high treatment value and strong pricing power. Understanding the

2026/08/15 Retrospective Analysis: Identifying Eton Pharmaceuticals (NASDAQ: ETON) at the Inflection Point

Identifying high-growth biopharmaceutical opportunities prior to broad market recognition requires a systematic framework combining product-level adoption metrics, operating leverage indicators, and valuation disconnects. This study presents a retrospective analysis of Eton Pharmaceuticals (NASDAQ: ETON) from the perspective of mid-2025—one year prior to its 2026 commercial expansion.

2026/08/14 Alnylam Pharmaceuticals (ALNY): From Pent-Up Demand to Normalized Growth—Re-evaluating Operating Leverage and Valuation After the Guidance Adjustment

Previous Essay Context: 2026/05/10 Alnylam Pharmaceuticals (ALNY): New Cardiomyopathy Drug & RNAi Technology Platform 1. What Happened: Guidance Reset Triggers Valuation Adjustment In my essay dated May 10, 2026, I highlighted that the sell-off across the U.S. healthcare sector was primarily a liquidity-driven event rather

2026/08/12 North American Energy Storage Deep Dive: S-Curve Inflection, AI Bubble Stress Testing, and Core Chain Winners

As the global energy transition accelerates and structural bottlenecks in the North American power grid become increasingly pronounced, Battery Energy Storage Systems (BESS) have evolved from ancillary components for renewables into a core pillar of next-generation power infrastructure. This study systematically analyzes the long-term investment logic of the